Role of serum pentraxin-3 levels in the evaluation of subclinical inflammation in children with Familial Mediterranean Fever
Öz
Purpose: Subclinical inflammation may persist in some patients with Familial Mediterranean Fever despite colchicine treatment. Pentraxin-3 is used as a potential biomarker of inflammatory activity in various inflammatory diseases. This study aimed to evaluate serum PTX-3 levels during attack and attack-free periods in children with Familial Mediterranean Fever and to investigate the possible association between serum PTX-3 levels and subclinical inflammation.
Materials and methods: Forty-five children diagnosed with Familial Mediterranean Fever and receiving colchicine treatment and 40 healthy controls were included. Serum pentraxin-3 levels and conventional acute-phase reactants were measured during attack and attack-free periods. Patients with at least one elevated acute-phase reactant during the attack-free period were considered to have subclinical inflammation.
Results: Pentraxin-3 levels and conventional acute-phase reactants were significantly higher during attack periods compared with attack-free periods and healthy controls (3.21±0.67 vs 1.90±0.15 vs 0.88±0.39 ng/mL, respectively; p<0.001). Serum pentraxin-3 levels were similar between patients with and without subclinical inflammation (1.9±0.05 vs 1.8±0.03 ng/mL; p=0.29); however, both subgroups had significantly higher pentraxin-3 levels than healthy controls (p=0.001). ROC analysis showed excellent diagnostic performance of PTX-3 for differentiating FMF patients from healthy controls, with an AUC of 1.000 (cut-off ≥1.80 ng/mL, sensitivity 100%, specificity 100%) during the attack period and 0.997 (cut-off ≥1.64 ng/mL, sensitivity 97.8%, specificity 100%) during the attack-free period.
Conclusion: Pentraxin-3 levels remained elevated in children with Familial Mediterranean Fever during both attack and attack-free periods compared with healthy controls, and PTX-3 discriminated FMF patients from healthy controls with excellent diagnostic accuracy during both the attack period (AUC=1.000) and the attack-free period (AUC=0.997). These findings suggest that PTX-3 may reflect persistent inflammatory activity in pediatric FMF patients and could serve as a useful marker of disease activity beyond overt clinical episodes. Larger prospective studies are needed to confirm these findings.
Anahtar Kelimeler
Familial Mediterranean Fever, pentraxin-3, subclinical inflammation, acute-phase reactants
Destekleyen Kurum
Proje Numarası
Etik Beyan
Kaynakça
- Ozturk, C., Halicioglu, O., Coker, I., Gulez, N., Sutçuoglu, S., Karaca, N., Aksu, G., & Kutukculer, N. (2012). Association of clinical and genetical features in FMF with focus on MEFV strip assay sensitivity in 452 children from western Anatolia, Turkey. Clinical rheumatology, 31(3), 493–501. https://doi.org/10.1007/s10067-011-1876
- The International FMF Consortium. (1997). Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell, 90(4), 797–807. https://doi.org/10.1016/s0092-8674(00)80539-5
- Stojanov, S., & Kastner, D. L. (2005). Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Current opinion in rheumatology, 17(5), 586–599. https://doi.org/10.1097/bor.0000174210.78449.6b
- Chae, J. J., Aksentijevich, I., & Kastner, D. L. (2009). Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy. British journal of haematology, 146(5), 467–478. https://doi.org/10.1111/j.1365-2141.2009.07733.x
- Ben-Zvi, I., & Livneh, A. (2011). Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nature reviews. Rheumatology, 7(2), 105–112. https://doi.org/10.1038/nrrheum.2010.181
- Korkmaz, C., Ozdogan, H., Kasapçopur, O., & Yazici, H. (2002). Acute phase response in familial Mediterranean fever. Annals of the rheumatic diseases, 61(1), 79–81. https://doi.org/10.1136/ard.61.1.79
- Livneh, A., Langevitz, P., Zemer, D., Padeh, S., Migdal, A., Sohar, E., & Pras, M. (1996). The changing face of familial Mediterranean fever. Seminars in arthritis and rheumatism, 26(3), 612–627. https://doi.org/10.1016/s0049-0172(96)80012-6
- Yalçinkaya, F., Cakar, N., Acar, B., Tutar, E., Güriz, H., Elhan, A. H., Oztürk, S., Kansu, A., Ince, E., Atalay, S., Girgin, N., Doğru, U., Aysev, D., & Ekim, M. (2007). The value of the levels of acute phase reactants for the prediction of familial Mediterranean fever associated amyloidosis: a case control study. Rheumatology international, 27(6), 517–522. https://doi.org/10.1007/s00296-006-0265-6
- Manukyan, G. P., Ghazaryan, K. A., Ktsoyan, Z.hA., Tatyan, M. V., Khachatryan, Z. A., Hakobyan, G. S., Mkrtchyan, V. A., Kelly, D., Coutts, A., & Aminov, R. I. (2008). Cytokine profile of Armenian patients with Familial Mediterranean fever. Clinical biochemistry, 41(10-11), 920–922. https://doi.org/10.1016/j.clinbiochem.2008.03.017
- Ahsen, A., Ulu, M. S., Yuksel, S., Demir, K., Uysal, M., Erdogan, M., & Acarturk, G. (2013). As a new inflammatory marker for familial Mediterranean fever: neutrophil-to-lymphocyte ratio. Inflammation, 36(6), 1357–1362. https://doi.org/10.1007/s10753-013-9675-2
